Atorvastatin Does Not Improve Liver Biochemistries or Mayo Risk Score in Primary Biliary Cirrhosis
| Autor: | Nancy Bach, Jorge Allina, Joseph A. Odin, Carol A. Bodian, Henry C. Bodenheimer, Carmen M. Stanca |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Physiology Atorvastatin Hypercholesterolemia Gastroenterology chemistry.chemical_compound Primary biliary cirrhosis Liver Function Tests Internal medicine medicine Humans Pyrroles Aged Retrospective Studies biology medicine.diagnostic_test Liver Cirrhosis Biliary Cholesterol business.industry Anticholesteremic Agents Middle Aged Hepatology medicine.disease Lipids Treatment Outcome Endocrinology chemistry Heptanoic Acids Biliary tract HMG-CoA reductase Quality of Life biology.protein Female lipids (amino acids peptides and proteins) Liver function Liver function tests business medicine.drug |
| Zdroj: | Digestive Diseases and Sciences. 53:1988-1993 |
| ISSN: | 1573-2568 0163-2116 |
| Popis: | Statin treatment reduces hypercholesterolemia and may be anti-inflammatory. Case reports noted decreased alkaline phosphatase and histological improvement following statin treatment in primary biliary cirrhosis. The objective of this study was to assess the long-term effects of statin treatment in primary biliary cirrhosis. A retrospective analysis compared clinical and biochemical data from 15 hypercholesterolemic individuals with primary biliary cirrhosis who were treated long-term with atorvastatin with an age and gender matched, primary biliary cirrhosis control group. A significant decrease in total cholesterol and low-density lipoprotein (LDL)-cholesterol (por = 0.002) was observed throughout atorvastatin treatment (median time 2.5 years). LDL-cholesterol levels in the control group were not significantly changed after 2 years (p0.050). No significant changes were noted in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin and Mayo Risk Score in either group (p0.05). Long-term atorvastatin treatment reduced LDL-cholesterol in primary biliary cirrhosis, but there was no evidence of any anti-inflammatory effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink